Valneva (VLA) Q4 2025 TU earnings summary

Executive summary

• Preliminary unaudited 2025 revenues reached €174.7 million, in line with guidance, with €157.9 million from product sales.

• Year-end cash position was €109.7 million, reflecting enhanced financial flexibility after debt refinancing.

• CEO's contract renewed for three years, ensuring leadership continuity.

Financial highlights

• Total revenues for 2025 were €174.7 million, up from €169.6 million in 2024, including variable consideration from a Lyme disease program collaboration.

• Product sales declined to €157.9 million from €163.3 million in 2024, mainly due to a 42.3% drop in third-party sales.

• Product sales excluding third-party sales grew 6.7% year-over-year, and 9% at constant exchange rates.

• Cash and cash equivalents stood at €109.7 million at year-end 2025, down from €168.3 million in 2024.

Outlook and guidance

• 2026 revenues are expected between €155–170 million, with product sales of €145–160 million.

• Lower 2026 product sales guidance reflects growth in core brands but continued wind-down of third-party sales.

• First Phase 3 data for the Lyme disease vaccine candidate anticipated in H1 2026, with regulatory submissions to follow if positive.

• First Phase 2 data for the tetravalent shigella vaccine candidate expected, with development decisions in H2 2026.

• Operating cash burn is expected to decline in 2026 while maintaining strategic R&D investments.